The latest price target for Alpha Tau Medical (NASDAQ:DRTS) was reported by Citigroup on March 11, 2026. The analyst firm set a price target for $9.00 expecting DRTS to rise to within 12 months (a possible 30.81% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Alpha Tau Medical (NASDAQ:DRTS) was provided by Citigroup, and Alpha Tau Medical maintained their buy rating.

There is no last upgrade for Alpha Tau Medical

The last downgrade for Alpha Tau Medical Ltd happened on March 4, 2026 when Piper Sandler changed their price target from $5 to $5 for Alpha Tau Medical Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alpha Tau Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alpha Tau Medical was filed on March 11, 2026 so you should expect the next rating to be made available sometime around March 11, 2027.

While ratings are subjective and will change, the latest Alpha Tau Medical (DRTS) rating was a maintained with a price target of $7.00 to $9.00. The current price Alpha Tau Medical (DRTS) is trading at is $6.88, which is out of the analyst’s predicted range.